Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1856)	6/18/1999 10:02:00 PM
From: yosi s	Read Replies (1) \| Respond to of 2028

Couple of things 1. Oxandrin is making headways in non healing wounds associated with patient with weight loss. 2. Always the elusive Japanese market for Growth Hormone. 3. Eventually Hepatitis B vaccine will be out for sale .(granted outside US). As for Oxandrin and generics there is no way some one can stop a generic from coming out. And be used in " off label". After all in written prescription you write the drug not the indication.... Good luck. Also they still have lots of cash. They can always buy and market another drug, or spend some money for drugs in late development stage. Lots of Biotech looking for funding out there.